5 research outputs found
ΠΠ ΠΠΠ£ΠΠΠ¦ΠΠ’ΠΠ ΠΠ«Π ΠΠΠΠΠΠΠΠΠΠ Π§ΠΠΠΠΠΠΠ
Natural focal tick-borne infections are widespread in the world and are characterized by a great etiologic diversity. Human granulocytotropic anaplasmosis (HGA), also transmitted by the bite of ticks became relevant in the last century of detection not only in animals but also in humans. The review provides an overview of the incidence of HGA in Russia and in the world, the prevalence of the habitat of mites, the diversity of reservoirs and sources of infection, mechanisms and pathways of transmission of the pathogen Anaplasma phagocytophilum and its biological features. The links and stages of the disease pathogenesis are considered in detail. Scientific data on the clinical course of the disease, the frequency and diversity of various symptoms of the disease, the issues of laboratory and differential diagnosis of anaplasmosis and its place in the nosological structure in patients with fever of unknown origin are discussed. At the same time, choosing a method of laboratory diagnostics it is necessary to take into account that molecular-genetic method (polymerase chain reaction PCR-diagnosis) allows to confirm the diagnosis quickly, while serological methods of research in a greater degree - to put a retrospective diagnosis. The article presents current data on the treatment of disease and methods of HGA prevention and also presents the results of the authorsβ own observations based on the survey of 63 patients. The analysis of Moscow residents treatment about sucking mites is carried out and summarized the incidence of infections transmitted by ixode mites. For the diagnosis of HGA and other tick-borne fever used a technique called polymerase chain reaction. It has been revealed that in Moscow, lime borreliosis occupies a leading place among mites associated with infections 60%, and the share of granulocytic anaplasmosis of a person is only 5% of patients. However, the study of ticks for the presence of HGA pathogens and other natural focal tick infections is carried out in insufficient volume (less than 30%), which should be considered in clinical and laboratory differential diagnosis, as well as preventive measures.ΠΡΠΈΡΠΎΠ΄Π½ΠΎ-ΠΎΡΠ°Π³ΠΎΠ²ΡΠ΅ ΡΡΠ°Π½ΡΠΌΠΈΡΡΠΈΠ²Π½ΡΠ΅ ΠΊΠ»Π΅ΡΠ΅Π²ΡΠ΅ ΠΈΠ½ΡΠ΅ΠΊΡΠΈΠΈ ΠΈΠΌΠ΅ΡΡ ΡΠΈΡΠΎΠΊΠΎΠ΅ ΡΠ°ΡΠΏΡΠΎΡΡΡΠ°Π½Π΅Π½ΠΈΠ΅ Π² ΠΌΠΈΡΠ΅ ΠΈ Ρ
Π°ΡΠ°ΠΊΡΠ΅ΡΠΈΠ·ΡΡΡΡΡ Π±ΠΎΠ»ΡΡΠΈΠΌ ΡΡΠΈΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΠΌ ΡΠ°Π·Π½ΠΎΠΎΠ±ΡΠ°Π·ΠΈΠ΅ΠΌ. ΠΡΠ°Π½ΡΠ»ΠΎΡΠΈΡΠ°ΡΠ½ΡΠΉ Π°Π½Π°ΠΏΠ»Π°Π·ΠΌΠΎΠ· ΡΠ΅Π»ΠΎΠ²Π΅ΠΊΠ° (ΠΠΠ§) - ΡΡΠ°Π½ΡΠΌΠΈΡΡΠΈΠ²Π½ΠΎΠ΅ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΠ΅, ΡΠ°ΠΊΠΆΠ΅ ΠΏΠ΅ΡΠ΅Π΄Π°ΡΡΠ΅Π΅ΡΡ ΡΠ΅ΡΠ΅Π· ΡΠΊΡΡ ΠΊΠ»Π΅ΡΠ΅ΠΉ, ΡΡΠ°Π»ΠΎ Π°ΠΊΡΡΠ°Π»ΡΠ½ΡΠΌ Ρ ΠΊΠΎΠ½ΡΠ° ΠΏΡΠΎΡΠ»ΠΎΠ³ΠΎ Π²Π΅ΠΊΠ° ΠΏΠΎΡΠ»Π΅ Π΅Π³ΠΎ Π²ΡΡΠ²Π»Π΅Π½ΠΈΡ Π½Π΅ ΡΠΎΠ»ΡΠΊΠΎ Ρ ΠΆΠΈΠ²ΠΎΡΠ½ΡΡ
, Π½ΠΎ ΠΈ Ρ ΡΠ΅Π»ΠΎΠ²Π΅ΠΊΠ°. Π Π΄Π°Π½Π½ΠΎΠΌ ΠΎΠ±Π·ΠΎΡΠ΅ ΠΏΡΠ΅Π΄ΡΡΠ°Π²Π»Π΅Π½Π° ΠΈΠ½ΡΠΎΡΠΌΠ°ΡΠΈΡ ΠΎ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π΅ΠΌΠΎΡΡΠΈ ΠΠΠ§ Π² Π ΠΎΡΡΠΈΠΈ ΠΈ Π² ΠΌΠΈΡΠ΅, ΡΠ°ΡΠΏΡΠΎΡΡΡΠ°Π½Π΅Π½Π½ΠΎΡΡΠΈ Π°ΡΠ΅Π°Π»Π° ΠΎΠ±ΠΈΡΠ°Π½ΠΈΡ ΠΊΠ»Π΅ΡΠ΅ΠΉ-ΠΏΠ΅ΡΠ΅Π½ΠΎΡΡΠΈΠΊΠΎΠ², ΠΎ ΡΠ°Π·Π½ΠΎΠΎΠ±ΡΠ°Π·ΠΈΠΈ ΡΠ΅Π·Π΅ΡΠ²ΡΠ°ΡΠΎΠ² ΠΈ ΠΈΡΡΠΎΡΠ½ΠΈΠΊΠΎΠ² ΠΈΠ½ΡΠ΅ΠΊΡΠΈΠΈ, ΠΌΠ΅Ρ
Π°Π½ΠΈΠ·ΠΌΠ°Ρ
ΠΈ ΠΏΡΡΡΡ
ΠΏΠ΅ΡΠ΅Π΄Π°ΡΠΈ Π²ΠΎΠ·Π±ΡΠ΄ΠΈΡΠ΅Π»Ρ, Π±ΠΈΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΡ
ΠΎΡΠΎΠ±Π΅Π½Π½ΠΎΡΡΡΡ
Π²ΠΎΠ·Π±ΡΠ΄ΠΈΡΠ΅Π»Ρ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡ Anaplasma phagocytophilum. ΠΠΎΠ΄ΡΠΎΠ±Π½ΠΎ ΡΠ°ΡΡΠΌΠΎΡΡΠ΅Π½Ρ Π·Π²Π΅Π½ΡΡ ΠΈ ΡΡΠ°Π΄ΠΈΠΈ ΠΏΠ°ΡΠΎΠ³Π΅Π½Π΅Π·Π° Π±ΠΎΠ»Π΅Π·Π½ΠΈ. ΠΡΠΈΠ²Π΅Π΄Π΅Π½Ρ Π½Π°ΡΡΠ½ΡΠ΅ Π΄Π°Π½Π½ΡΠ΅ ΠΎΠ± ΠΎΡΠΎΠ±Π΅Π½Π½ΠΎΡΡΡΡ
ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΡΠ΅ΡΠ΅Π½ΠΈΡ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡ, ΠΎ ΡΠ°ΡΡΠΎΡΠ΅ ΠΈ ΡΠ°Π·Π½ΠΎΠΎΠ±ΡΠ°Π·ΠΈΠΈ ΡΠ°Π·Π»ΠΈΡΠ½ΡΡ
ΡΠΈΠΌΠΏΡΠΎΠΌΠΎΠ² Π±ΠΎΠ»Π΅Π·Π½ΠΈ. ΠΠ±ΡΡΠΆΠ΄Π°ΡΡΡΡ Π²ΠΎΠΏΡΠΎΡΡ Π»Π°Π±ΠΎΡΠ°ΡΠΎΡΠ½ΠΎΠΉ ΠΈ Π΄ΠΈΡΡΠ΅ΡΠ΅Π½ΡΠΈΠ°Π»ΡΠ½ΠΎΠΉ Π΄ΠΈΠ°Π³Π½ΠΎΡΡΠΈΠΊΠΈ Π°Π½Π°ΠΏΠ»Π°Π·ΠΌΠΎΠ·Π° ΠΈ Π΅Π³ΠΎ ΠΌΠ΅ΡΡΠΎ Π² Π½ΠΎΠ·ΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΎΠΉ ΡΡΡΡΠΊΡΡΡΠ΅ Ρ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ Π»ΠΈΡ
ΠΎΡΠ°Π΄ΠΊΠΎΠΉ Π½Π΅ΡΡΠ½ΠΎΠ³ΠΎ Π³Π΅Π½Π΅Π·Π°. ΠΡΠΈ Π²ΡΠ±ΠΎΡΠ΅ ΠΌΠ΅ΡΠΎΠ΄Π° Π»Π°Π±ΠΎΡΠ°ΡΠΎΡΠ½ΠΎΠΉ Π΄ΠΈΠ°Π³Π½ΠΎΡΡΠΈΠΊΠΈ Π½ΡΠΆΠ½ΠΎ ΡΡΠΈΡΡΠ²Π°ΡΡ, ΡΡΠΎ ΠΌΠΎΠ»Π΅ΠΊΡΠ»ΡΡΠ½ΠΎ-Π³Π΅Π½Π΅ΡΠΈΡΠ΅ΡΠΊΠΈΠΉ ΠΌΠ΅ΡΠΎΠ΄ (ΠΏΠΎΠ»ΠΈΠΌΠ΅ΡΠ°Π·Π½Π°Ρ ΡΠ΅ΠΏΠ½Π°Ρ ΡΠ΅Π°ΠΊΡΠΈΡ ΠΠ¦Π -Π΄ΠΈΠ°Π³Π½ΠΎΡΡΠΈΠΊΠ°) ΠΏΠΎΠ·Π²ΠΎΠ»ΡΠ΅Ρ Π±ΡΡΡΡΠΎ ΠΏΠΎΠ΄ΡΠ²Π΅ΡΠ΄ΠΈΡΡ Π΄ΠΈΠ°Π³Π½ΠΎΠ·, Π° ΡΠ΅ΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΠΌΠ΅ΡΠΎΠ΄Ρ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ Π² Π±ΠΎΠ»ΡΡΠ΅ΠΉ ΡΡΠ΅ΠΏΠ΅Π½ΠΈ - ΠΏΠΎΡΡΠ°Π²ΠΈΡΡ ΡΠ΅ΡΡΠΎΡΠΏΠ΅ΠΊΡΠΈΠ²Π½ΡΠΉ Π΄ΠΈΠ°Π³Π½ΠΎΠ·. ΠΡΠ΅Π΄ΡΡΠ°Π²Π»Π΅Π½Ρ Π°ΠΊΡΡΠ°Π»ΡΠ½ΡΠ΅ Π΄Π°Π½Π½ΡΠ΅ ΠΏΠΎ Π»Π΅ΡΠ΅Π½ΠΈΡ Π±ΠΎΠ»Π΅Π·Π½ΠΈ ΠΈ ΠΌΠ΅ΡΠΎΠ΄Π°ΠΌ ΠΏΡΠΎΡΠΈΠ»Π°ΠΊΡΠΈΠΊΠΈ ΠΠΠ§. Π ΡΡΠ°ΡΡΠ΅ ΡΠ°ΠΊΠΆΠ΅ ΠΏΡΠΈΠ²ΠΎΠ΄ΡΡΡΡ ΡΠ΅Π·ΡΠ»ΡΡΠ°ΡΡ ΡΠΎΠ±ΡΡΠ²Π΅Π½Π½ΡΡ
Π½Π°Π±Π»ΡΠ΄Π΅Π½ΠΈΠΉ Π°Π²ΡΠΎΡΠΎΠ² Π½Π° ΠΎΡΠ½ΠΎΠ²Π΅ ΠΎΠ±ΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ 63 ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ². ΠΡΠΎΠ²Π΅Π΄Π΅Π½ Π°Π½Π°Π»ΠΈΠ· ΡΠ»ΡΡΠ°Π΅Π² ΠΎΠ±ΡΠ°ΡΠ΅Π½ΠΈΡ ΠΆΠΈΡΠ΅Π»Π΅ΠΉ Π³. ΠΠΎΡΠΊΠ²Ρ ΠΏΠΎ ΠΏΠΎΠ²ΠΎΠ΄Ρ ΠΏΡΠΈΡΠ°ΡΡΠ²Π°Π½ΠΈΡ ΠΊΠ»Π΅ΡΠ΅ΠΉ ΠΈ ΠΎΠ±ΠΎΠ±ΡΠ΅Π½Ρ ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»ΠΈ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π΅ΠΌΠΎΡΡΠΈ ΠΈΠ½ΡΠ΅ΠΊΡΠΈΡΠΌΠΈ, ΠΏΠ΅ΡΠ΅Π΄Π°ΡΡΠΈΠΌΠΈΡΡ ΠΈΠΊΡΠΎΠ΄ΠΎΠ²ΡΠΌΠΈ ΠΊΠ»Π΅ΡΠ°ΠΌΠΈ. ΠΠ»Ρ Π΄ΠΈΠ°Π³Π½ΠΎΡΡΠΈΠΊΠΈ ΠΠΠ§ ΠΈ Π΄ΡΡΠ³ΠΈΡ
ΠΊΠ»Π΅ΡΠ΅Π²ΡΡ
Π»ΠΈΡ
ΠΎΡΠ°Π΄ΠΎΠΊ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π»ΠΈ ΠΌΠ΅ΡΠΎΠ΄ ΠΏΠΎΠ»ΠΈΠΌΠ΅ΡΠ°Π·Π½ΠΎΠΉ ΡΠ΅ΠΏΠ½ΠΎΠΉ ΡΠ΅Π°ΠΊΡΠΈΠΈ. ΠΡΡΠ²Π»Π΅Π½ΠΎ, ΡΡΠΎ Π² Π³. ΠΠΎΡΠΊΠ²Π΅ ΡΡΠ΅Π΄ΠΈ Π°ΡΡΠΎΡΠΈΠΈΡΠΎΠ²Π°Π½Π½ΡΡ
Ρ ΠΊΠ»Π΅ΡΠ°ΠΌΠΈ ΠΈΠ½ΡΠ΅ΠΊΡΠΈΠΉ Π»ΠΈΠ΄ΠΈΡΡΡΡΠ΅Π΅ ΠΌΠ΅ΡΡΠΎ Π·Π°Π½ΠΈΠΌΠ°Π΅Ρ ΠΠ°ΠΉΠΌ-Π±ΠΎΡΡΠ΅Π»ΠΈΠΎΠ· (60%), Π° Π΄ΠΎΠ»Ρ Π³ΡΠ°Π½ΡΠ»ΠΎΡΠΈΡΠ°ΡΠ½ΠΎΠ³ΠΎ Π°Π½Π°ΠΏΠ»Π°Π·ΠΌΠΎΠ·Π° ΡΠ΅Π»ΠΎΠ²Π΅ΠΊΠ° ΡΠΎΡΡΠ°Π²Π»ΡΠ΅Ρ ΡΠΎΠ»ΡΠΊΠΎ 5% Π±ΠΎΠ»ΡΠ½ΡΡ
. ΠΠΌΠ΅ΡΡΠ΅ Ρ ΡΠ΅ΠΌ Π²ΡΡΠ²Π»Π΅Π½ΠΎ, ΡΡΠΎ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠ΅ ΠΊΠ»Π΅ΡΠ΅ΠΉ Π½Π° ΠΏΡΠΈΡΡΡΡΡΠ²ΠΈΠ΅ Ρ Π½ΠΈΡ
Π²ΠΎΠ·Π±ΡΠ΄ΠΈΡΠ΅Π»Π΅ΠΉ ΠΠΠ§ ΠΈ Π΄ΡΡΠ³ΠΈΡ
ΠΏΡΠΈΡΠΎΠ΄Π½ΠΎ-ΠΎΡΠ°Π³ΠΎΠ²ΡΡ
ΠΊΠ»Π΅ΡΠ΅Π²ΡΡ
ΠΈΠ½ΡΠ΅ΠΊΡΠΈΠΉ ΠΏΡΠΎΠ²ΠΎΠ΄ΠΈΡΡΡ Π² Π½Π΅Π΄ΠΎΡΡΠ°ΡΠΎΡΠ½ΠΎΠΌ ΠΎΠ±ΡΠ΅ΠΌΠ΅ (ΠΌΠ΅Π½Π΅Π΅ 30%), ΡΡΠΎ Π½Π΅ΠΎΠ±Ρ
ΠΎΠ΄ΠΈΠΌΠΎ ΡΡΠΈΡΡΠ²Π°ΡΡ ΠΏΡΠΈ ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΎΠΉ ΠΈ Π»Π°Π±ΠΎΡΠ°ΡΠΎΡΠ½ΠΎΠΉ Π΄ΠΈΡΡΠ΅ΡΠ΅Π½ΡΠΈΠ°Π»ΡΠ½ΠΎΠΉ Π΄ΠΈΠ°Π³Π½ΠΎΡΡΠΈΠΊΠ΅, Π° ΡΠ°ΠΊΠΆΠ΅ ΠΏΡΠΎΠ²Π΅Π΄Π΅Π½ΠΈΠΈ ΠΏΡΠΎΡΠΈΠ»Π°ΠΊΡΠΈΡΠ΅ΡΠΊΠΈΡ
ΠΌΠ΅ΡΠΎΠΏΡΠΈΡΡΠΈΠΉ
the influence of genetic factors on the effectiveness, safety and tolerability of antiretroviral therapy in patients with hiv infection
This article provides an overview of the existing literature on the pharmacogenetic determinants of exposure and toxicity of antiretroviral drugs, as well as on genetic markers associated with the rate of disease progression. In addition, this article looks at current clinical opportunities as well as genetics in HIV drug development. Large-scale, integrated approaches to the genome are expected to significantly change the knowledge landscape in the future. Β© 2021 Interregional public organization Association of infectious disease specialists of Saint-Petersburg and Leningrad region (IPO AIDSSPbR). All rights reserved